Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients

Aleksandra Butrym; Justyna Rybka; Dagmara Baczyńska; Rafał Poręba; Kazimierz Kuliczkowski; Grzegorz Mazur

doi:10.18632/oncotarget.7172

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients

Aleksandra Butrym _, Justyna Rybka, Dagmara Baczyńska, Rafał Poręba, Kazimierz Kuliczkowski and Grzegorz Mazur

PDF | HTML | How to cite

Oncotarget. 2016; 7:30250-30257. https://doi.org/10.18632/oncotarget.7172

Metrics: PDF 1502 views | HTML 1808 views | ?

Abstract

Aleksandra Butrym1,2, Justyna Rybka1, Dagmara Baczyńska3, Rafał Poręba4, Kazimierz Kuliczkowski1, Grzegorz Mazur4

1Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland

2Department of Physiology, Wroclaw Medical University, Wroclaw, Poland

3Department of Forensic Medicine, Molecular Techniques Unit, Wroclaw Medical University, Wroclaw, Poland

4Department of Internal, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland

Correspondence to:

Aleksandra Butrym, e-mail: [email protected]

Keywords: miR-29c, acute myeloid leukemia, azacitidine, response to therapy, expression

Received: October 05, 2015 Accepted: January 23, 2016 Published: February 03, 2016

ABSTRACT

Acute myeloid leukemia (AML) is a heterogeneous disease with different clinical course and prognosis. microRNA-29 (miR-29) family of non-coding small RNAs can play an important role in pathogenesis of AML, but also can influence response to therapy.

The purpose of the study was to evaluate miR-29c expression in AML patients in relationship to clinical parameters and response to chemotherapy, including azacitidine.

Materials and Methods: miR-29c expression has been analyzed using RT-PCR in 95 bone marrow specimens from newly diagnosed AML patients in comparison to 20 healthy subject.

Results: We showed up-regulated miR-29c expression in AML patients which was linked also to higher risk of disease relapse after achieving complete remission. In subset of elderly AML patients treated with azacitidine, low miR-29c expression at diagnosis correlated with good response to therapy.

Conclusions: miR-29c is of prognostic value and influences response to azacitidine treatment in older AML patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7172

Publication Alerts

Research Papers:

Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients

Abstract